DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice

por Ma, MingJie, Hasegawa, Yu, Koibuchi, Nobutaka, Toyama, Kensuke, Uekawa, Ken, Nakagawa, Takashi, Lin, Bowen, Kim-Mitsuyama, Shokei
Publicado 2015

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice

por Lin, Bowen, Koibuchi, Nobutaka, Hasegawa, Yu, Sueta, Daisuke, Toyama, Kensuke, Uekawa, Ken, Ma, MingJie, Nakagawa, Takashi, Kusaka, Hiroaki, Kim-Mitsuyama, Shokei
Publicado 2014

DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure

por Koibuchi, Nobutaka, Hasegawa, Yu, Katayama, Tetsuji, Toyama, Kensuke, Uekawa, Ken, Sueta, Daisuke, Kusaka, Hiroaki, Ma, MingJie, Nakagawa, Takashi, Lin, Bowen, Kim-Mitsuyama, Shokei
Publicado 2014